The TGA has issued 15 infringement notices totalling $39,960 to a New South Wales based individual for alleged unlawful importation of the prescription-only medicines ivermectin and doxycycline.
The TGA has cancelled the listed complementary medicine FatBlaster Max (AUST L 348163) from the Australian Register of Therapeutic Goods (ARTG) for alleged breaches of the Therapeutic Goods Act 1989.
The TGA has issued one infringement notice of $2,664 to a Sydney based individual for alleged unlawful importation of unregistered anaesthetic products.
The TGA has issued three infringement notices totalling $39,960 to New South Wales based company Khazanah Nasional Pty Ltd for alleged unlawful advertising of disposable liquid nicotine vaping products.
The TGA has determined that the BBIBP-CorV (Sinopharm) COVID-19 vaccine will be 'recognised' for all ages for the purpose of establishing a traveller's vaccination status when entering Australia.
The TGA has received and commenced evaluation of an application to extend the use of its COVID-19 vaccine, SPIKEVAX, to children aged 6 months to 5 years old.
On 7 April 2022, the TGA announced receipt of an application from GlaxoSmithKline (GSK) Australia Pty Ltd for a higher (1000 mg) dose of its COVID-19 treatment, XEVUDY (sotrovimab).